Zetone Biopharma

Zetone Biopharma is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of next-generation immunotherapies for cancer and autoimmune diseases. The company's core expertise lies in protein engineering, which it applies to the CD47/SIRPα axis to create therapies with enhanced safety profiles and potent anti-tumor activity. Its lead candidate, ZT-001, is a recombinant human SIRPα-Fc fusion protein currently in Phase 1/2 clinical development for advanced solid tumors and hematologic malignancies. Zetone aims to address the limitations of current checkpoint inhibitors through its pipeline of multi-functional fusion proteins and bispecific antibodies. The company is backed by leading venture capital firms, including HighLight Capital and 3E Bioventures.